Test Catalog

Test Id : MMLYP

Order This Test

Antimicrobial Susceptibility Panel, Yeast, Varies

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Determining in vitro quantitative antifungal susceptibility (minimum inhibitory concentration) of non-fastidious yeast

 

As an aid in the management of certain circumstances, such as:

-Refractory oropharyngeal infections due to Candida species in patients who appear to be experiencing therapeutic failure with standard agents at standard doses

-Invasive infections due to Candida species when the utility of azole antifungal agents is uncertain (eg, when the infection is due to a non-Candida albicans organism)

Highlights

Antifungals included in the assay are amphotericin B, anidulafungin, caspofungin, fluconazole, itraconazole, isavuconazole, rezafungin, micafungin, posaconazole, and voriconazole.

Additional Tests
Lists tests that are always performed, at an additional charge, with the initial tests.

Test Id Reporting Name Available Separately Always Performed
SYP Susceptibility Yeast Panel No, (Bill Only) Yes

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, the susceptibility yeast panel will be performed at an additional charge. All yeast submitted will have susceptibility testing performed and billed as appropriate.

Method Name
A short description of the method used to perform the test

Minimum Inhibitory Concentration (MIC)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Susceptibility Panel, Yeast

Aliases
Lists additional common names for a test, as an aid in searching

Abelcet (Amphotericin B)

Amphotericin B (Abelcet)

Anidulafungin (ERAXIS)

CANCIDAS (Caspofungin)

Caspofungin (CANCIDAS)

Diflucan (Fluconazole)

ERAXIS (Anidulafungin)

Fluconazole (Diflucan)

Itraconazole (Sporanox)

Micafungin (Mycamine)

NOXAFIL (Posaconazole)

Posaconazole (NOXAFIL)

Sporanox (Itraconazole)

Susceptibility Panel, Yeast

Susceptibility Testing

Vfend (Voriconazole)

Voriconazole (Vfend)

Yeast Susceptibility Panel

Isavuconazole (Cresemba)

Cresemba (Isavuconazole)

Rezafungin (Rezzayo)

Rezzayo (Rezafungin)

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, the susceptibility yeast panel will be performed at an additional charge. All yeast submitted will have susceptibility testing performed and billed as appropriate.

Specimen Type
Describes the specimen type validated for testing

Varies

Shipping Instructions

1. See Infectious Specimen Shipping Guidelines

2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.

Necessary Information

Specimen source and suspected organism identification are required. If identification of organism is not provided, FUNID / Culture Referred for Identification, Fungus, Varies will be performed at an additional charge.

ORDER QUESTIONS AND ANSWERS

Question ID Description Answers
Q00M0040 Specimen Source (Required) and Organism Identification(Required unless concurrent identification test is ordered)

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Specimen Type: Organism in pure culture

Supplies: Infectious Container, Large (T146)

Container/Tube: Sabouraud's dextrose agar slant

Specimen Volume: Infecting yeast isolate

Collection Instructions: Organism must be in pure culture, actively growing. Do not submit mixed cultures.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

See Specimen Required

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Agar plate Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
Refrigerated

Useful For
Suggests clinical disorders or settings where the test may be helpful

Determining in vitro quantitative antifungal susceptibility (minimum inhibitory concentration) of non-fastidious yeast

 

As an aid in the management of certain circumstances, such as:

-Refractory oropharyngeal infections due to Candida species in patients who appear to be experiencing therapeutic failure with standard agents at standard doses

-Invasive infections due to Candida species when the utility of azole antifungal agents is uncertain (eg, when the infection is due to a non-Candida albicans organism)

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, the susceptibility yeast panel will be performed at an additional charge. All yeast submitted will have susceptibility testing performed and billed as appropriate.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Candida species are the fourth leading cause of nosocomial infections and are frequent causes of community-acquired infections.

 

Antifungal susceptibility testing may aid in the management of patients with invasive infections due to Candida species or patients who appear to be experiencing therapeutic failure.

 

The Clinical Laboratory Standards Institute has approved the use of a broth microdilution method for determining the susceptibility of Candida species.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Results reported in mcg/mL

Interpretation
Provides information to assist in interpretation of the test results

The Clinical and Laboratory Standards Institute method, breakpoints, and interpretive criteria are used.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

The assay cannot be used for minimum inhibitory concentration determinations for the dimorphic yeast or filamentous fungi.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50

Method Description
Describes how the test is performed and provides a method-specific reference

Yeast susceptibility is determined by colorimetric microdilution broth method using TREK Sensititre YeastOne Y011 Susceptibility Plate. Each plate is setup with appropriate dilutions of antifungal agents and a colorimetric indicator. After inoculation with a standardized suspension of organism in inoculum medium and incubation at 35 degrees C for 24 to 48 hours; the minimum inhibitory concentrations for the test organism are determined by observing the lowest antifungal concentration showing inhibition of growth as evidenced by no color change of the test medium.(Clinical and Laboratory Standards Institute [CLSI]: Performance Standards for Antifungal Susceptibility Testing of Yeasts. 2nd ed. CLSI supplement M60. CLSI; 2020; CLSI: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI standard M27. CLSI; 2017)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Saturday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

3 to 7 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

30 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

87186

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MMLYP Susceptibility Panel, Yeast 29577-4
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
MMLYP Susceptibility Panel, Yeast 29577-4

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
Test Changes - Method 2024-05-30
Test Status - Test Resumed 2024-04-11
Test Status - Test Delay 2024-04-04
Test Status - Test Resumed 2023-01-18
Test Status - Test Delay 2023-01-06